Amino Acids

, Volume 42, Issue 4, pp 1087–1096

Glycation research in amino acids: a place to call home



This is an introduction to a collection of review articles by leading investigators in the field of protein glycation research, see following articles in this issue. With this we launch a section of this journal now established for presentation of research results, reviews and commentaries on protein glycation and related topics. Glycation is the spontaneous, non-enzymatic reaction of protein with saccharides and saccharide derivatives. Although studied in the modern scientific era for over 100 years, its importance in the biology, medicine, food and nutrition, pharmacology and toxicology, and technological processing remains intriguingly undisclosed. In this section of amino acids, research on glycation is a qualifier for publication. Glycation research now has a place to call home.

Glycation: nomenclature and classification

In 1985 the Nomenclature Committee of International Union of Biochemistry and the International Union of Pure and Applied Chemistry recommended the term glycation for “all reactions that link a sugar to a protein or a peptide, whether or not catalysed by an enzyme”—drafted by Sharon (1986). In a subsequent review in 1993, Lis and Sharon distinguished between enzymatic modification of proteins by saccharides in processes of protein glycosylation forming glycoproteins and non-enzymatic modification of proteins by saccharides in processes of protein glycation forming glycated proteins (Lis and Sharon 1993). This eventually led to selective use of the term glycation for non-enzymatic modification of proteins by saccharides such that it is now accepted nomenclature. In older scientific literature, one of the most prominent glycated proteins, haemoglobin, has been called glycosylated haemoglobin, non-enzymatic glycosylated haemoglobin, glycohaemoglobin, glucosylated haemoglobin and other variants.

Protein glycation involves the non-enzymatic attachment of a reducing sugar or sugar derivative to a protein. The term “reducing” related to the classical activity of saccharides with solution species with free aldehyde or ketone groups which reduced Benedict’s solution (Benedict 1909). Glycation is not available to non-reducing oligosaccharides where aldehyde or ketone groups of component monosaccharides have been converted to ketal and acetal groups of glycosidic bonds—such as in sucrose (table sugar). In its earliest development, protein glycation was thought to be restricted to modification of amino groups of lysine residue side chains and N-terminal amino acid residues. In more recent times, glycation of arginine residues by dicarbonyl metabolites has emerged as a major feature of protein glycation in physiological systems. There is also involvement of cysteine residues.

Glycation of proteins occurs by a complex series of sequential and parallel reactions called collectively the Maillard reaction—named after the leading pioneer of glycation research, Louis Camille Maillard (1878–1936). Many different adducts may be formed–some of which are fluorescent and coloured “browning pigments”. In the physiological setting, one of the important saccharides participating in glycation of mammalian metabolism is glucose, and some of the most important saccharide derivatives are the reactive dicarbonyl metabolites such as methylglyoxal (MG).

Historically, glycation of lysyl side chain and N-terminal amino groups by glucose was the major glycation process studied in the glycation of proteins. This has given rise to the classification of early and advanced glycation processes. Glucose reacts with amino groups to initially form a glycosylamine which dehydrates to form a Schiff’s base. The Schiff’s base undergoes an Amadori rearrangement to form N-(1-deoxy-d-fructos-1-yl)amino acids or fructosamine (Hodge 1955). Glycation of proteins by glucose to the fructosamine stage has been classified as early glycation. Glycosylamine, Schiff’s base and fructosamines are considered to be early stage glycation adducts. In later stage reactions fructosamine degrades to many stable end-stage adducts called advanced glycation endproducts (AGEs)—Fig. 1a. This is a broader definition of AGEs than originally given by Cerami as “brown fluorescent pigments which crosslink proteins” (Cerami 1986). Inconsistencies in the application of this classification and nomenclature have recently arisen because glucose may degrade when unattached to protein to form reactive α-oxoaldehydes. α-Oxoaldehydes are potent glycating agents and react with proteins to form AGEs directly. The Schiff’s base adduct may also degrade via non-Amadori rearrangement reaction pathways to α-oxoaldehydes which also leads to the formation of AGEs. The latter are also formed by the direct modification of proteins by α-oxoaldehydes produced by the degradation of glycolytic intermediates and lipid peroxidation. Important α-oxoaldehyde or dicarbonyl glycating agents are glyoxal, MG, and 3-deoxyglucosone (3-DG)—Fig. 1b. Therefore, AGEs may be formed in glycation by glucose in pre- and post-Amadori product reactions, and indeed in processes where an Amadori product is not a precursor. AGEs may be formed in both the early and late stages of glycation processes. The term “advanced glycation endproducts” is a misnomer in that AGEs are formed in both early and later, advanced stages of the Maillard reaction. The concept of early and advanced glycation adducts is, however, simple and the nomenclature of fructosamine and AGEs is convenient, widely used, understood and accepted. Molecular structures of fructosamines and some common AGEs are given in Fig. 2.
Fig. 1

Protein glycation. a Early glycation and sources of advanced glycation endproducts (AGEs). b Some important glycating agents. c Classification of protein glycation adduct residues, peptides and free adducts. The 12 kDa discrimination for protein glycation adduct residues and peptides is empirical and relates to the pore size of ultrafiltration membrane used in separation

Fig. 2

Molecular structures of glycation adduct residues. a Early glycation adducts formed by glycation with glucose: fructosamines. R indicates the amino acid side chain. bf Advanced glycation endproducts. b Hydroimidazolones. c Monolysine adducts. d Imidazolium and other crosslinks. e Fluorophores. f Other structures. The peptide linkage is shown cut away for clarity. For the corresponding free adducts at physiological pH, the N-terminal amino group is protonated –NH3+ and the C-terminal carbonyl is a carboxylate –CO2 moiety. Ionisation status is given for the major solution form at pH 7.4

Further classification of AGEs has been made to relate to the mechanism of AGE formation. “Glycoxidation” is a term in general use for glycation processes in which oxidation is involved and the AGEs formed thereby have been called “glycoxidation products” (Baynes 1991). The AGEs pentosidine and CML are examples of glycoxidation products. Where aldehyde substrates of glycation are formed by lipid peroxidation, the endstage adducts have been called advanced lipoxidation adducts (ALEs). CML is also an ALE as it may be formed from glyoxal generated from lipid peroxidation (Fu et al. 1996) Other classifications were devised but currently are not in widespread use (Baynes and Thorpe 2000)—Fig. 1.

Glycation adducts of proteins are formed by modification of amino acid residues of proteins with monosaccharides or saccharide derivatives. They are appropriately called, therefore, glycation adduct residues—such as the fructosamine residues of glycated haemoglobin and AGE residues of AGE-modified proteins. Glycated proteins undergo proteolysis during digestion of ingested proteins in food and turnover of proteins in tissues and body fluids. Proteolysis of glycated proteins forms lower molecular mass glycated peptides and glycated amino acids. The latter are conveniently called glycation free adducts. Glycation free adducts are acutely sensitive to change in renal clearance in mammalian systems (Rabbani et al. 2007)—Fig. 1c.

Glycation adduct residues of proteins have been called “protein-bound” glycation adducts—particularly for AGEs in renal failure research. This is discouraged as it is a misnomer; part of the glycation adduct structure is an integral part of the protein and hence binding of discrete glycation adduct is not involved. There may be non-covalent binding of discrete binding of glycation free adducts to plasma protein in some instances, particularly at the high levels of glycation free adducts found in renal failure (Agalou et al. 2005; Rabbani et al. 2007) and hence it is important to be able to distinguish between glycation adduct residues and binding of free adducts.

Historical background of glycation

In 1908, Arthur Robert Ling (1861–1937) produced flavoured and coloured compounds from thermal drying of proteins with sugars. He wrote “When these amino-compounds produced from proteins are heated at 120–140°C with sugars such as ordinary glucose or maltose, which are produced at this stage of process, combination occurs. The precise nature of the compounds produced is unknown to me, but they are probably glucosamine-like bodies” (Ling 1908). He also described the heating of glucose with asparagine producing browning pigments. These were amongst the earliest recorded adducts formed between glucose and an amino acid. In 1912, Maillard investigated the reaction between glucose and glycine on heating. He proposed that the brown pigmented product or melanoids involved an initial interaction between amines and saccharides forming Schiff’s base adducts (Maillard 1912a). The non-enzymatic reaction of amino acids with sugars now bears his name, the “Maillard reaction”. Maillard acknowledged the prior work of Ling in a later paper (Maillard 1912b). In 1913 the glyoxalase system that catalyses the conversion of MG to lactate and thereby suppresses dicarbonyl glycation in physiological systems was discovered (Dakin and Dudley 1913; Neuberg 1913). In 1925 and 1931, Mario Amadori demonstrated that the condensation of d-glucose with aromatic amines p-phenetidine, p-anisidine or p-toluidine gave two structurally different isomers which were not anomers (Amadori 1929a, b). One of the isomers was more labile than the other towards hydrolysis and was also more susceptible to decomposition on standing in the solid state in air. He correctly recognised this as the N-glycosylamine but he mistakenly thought that the more stable isomer was a Schiff’s base, overlooking its resistance to acid hydrolysis (Amadori 1929a). In 1936, Kuhn and Dansi found that the stable isomer was not a Schiff’s base but rather the product of a molecular rearrangement. They also confirmed that the labile isomer was in fact the N-substituted glycosylamine (Kuhn and Dansi 1936). In 1937, Kuhn and Weygand reported the structure of the Amadori’s stable isomer, which was the unbranched N-substituted 1-amino-1-deoxy-2-ketose. Kuhn and Weygand later called the reaction the Amadori rearrangement involving generally aldoses and amines (Kuhn and Weygand 1937). In 1953, Hodge suggested that the Maillard reaction involved formation of a Schiff’s base followed by Amadori rearrangement in the early stages. He also suggested that fructosamine degraded to glucosone and other adducts via enolisation, oxidation and fragmentation reactions (Hodge 1953). An excellent history of the early days of glycation research was given by Kawamura (1983).

In 1958, Allan et al. reported the first example of a glycated protein in vivo. They reported the presence of a negatively charged component of haemoglobin in human red blood cells (Allen et al. 1958). This was a variant of glycated haemoglobin HbA1. It was first characterized as a glycated haemoglobin by Bookchin and Gallop (1968), its increase in diabetes described by Rahbar (1968), reactions leading to its formation were characterized by Bunn and his co-workers (1975) and the use of the glucose adduct glycated haemoglobin HbA1c for monitoring the glycemic control in diabetic patients was proposed by Anthony Cerami and coworkers (Koenig et al. 1976). Percentage of HbA1c is now a routine clinical diagnostic measure of glycaemic control of diabetic patients worldwide.

In 1960, Anet reported the degradation of a fructosamine (N,N-difructosylglycine) to 3-deoxyglucosone (Anet 1960). This was the first example of the importance of fructosamine dehydration to a 3-deoxy-2-oxoaldehyde. Kato also isolated 3-deoxyglucosone and 3-deoxypentosone from the browning reactions of glucose and ribose with an amine (Kato 1960; Kato et al. 1969, 1989). These reactive α-oxoaldehyde products of the Maillard reaction are now seen as important precursors of glycation adduct formation in biological systems.

In 1973, Bonsignore et al. (1973) presented the first evidence that a triosephosphate, glyceraldehyde-3-phosphate, degraded non-enzymatically under physiological conditions to form MG. In 1977, Takahashi described the reaction of amino acids with glyoxal derivatives, including glyoxal and MG. Arginine was identified as the predominant amino acid modified and a hydroimidazolone was one molecular structure proposed for the adducts (Takahashi 1977). Although no supporting analytical data were given, this was later to be confirmed as a major AGE in physiological systems and some foodstuffs (Ahmed et al. 2002; Henle et al. 1994; Thornalley et al. 2003).

In 1980, Nakayama et al. reported the formation of 6-(2-formyl-5-hydroxymethylpyrrol-1-yl)-l-norleucine from 3-deoxyglucosone and lysyl residues in proteins, now commonly known as pyrraline—an AGE (Nakayama et al. 1980). Hayashi and Namiki presented evidence for the fragmentation of the saccharide moiety early in the Maillard reaction, leading to the formation of α-oxoaldehydes. Evidence for the formation of glyoxal and MG established saccharide fragmentation as a new series of reaction pathways in Maillard chemistry, now collectively called the Namiki pathway (Hayashi and Namiki 1980).

In 1984, a product formed from the degradation of Amadori product, 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole (FFI), was reported by Pongor et al. (1984). Wolff and co-workers reported the slow oxidative degradation of monosaccharides under physiological conditions to form the corresponding α-oxoaldehyde and hydrogen peroxide. This process was called monosaccharide autoxidation (Wolff et al. 1984).

In 1986, Cerami first used the term advanced glycation endproducts (AGE) to refer to “brown fluorescent pigments which crosslink proteins” formed from the degradation of fructosamine (Cerami 1986). Brownlee et al. reported increased collagen cross-linking in the arterial walls of diabetic rats and associated fluorescence characteristic of AGE compounds. The nucleophilic hydrazine derivative, aminoguanidine (Pimagedine™), inhibited the formation of AGEs and diabetes-induced protein crosslinking (Brownlee et al. 1986). Ahmed et al. also reported the formation of Nε-carboxymethyl-lysine (CML) from the oxidative degradation of glycated proteins and also noticed that these two compounds were present in human urinary metabolite (Ahmed et al. 1986). CML was later found to be formed by the reaction of lysine residues with ascorbate and glyoxal formed in lipid peroxidation and is now one of the most studied AGEs in glycation research (Thorpe and Baynes 2002).

In 1988, Thornalley presented evidence linking hyperglycaemia in diabetes mellitus with increased flux of formation and concentration of MG (Thornalley 1988). Glycation by MG was later to be proposed as one of the key pathways driving the development of vascular complications of diabetes (Brownlee 2001).

In 1989, Monnier and Sell isolated an acid stable fluorescent compound from collagen—“pentosidine”. It was a crosslink formed from a pentose moiety with lysine and arginine residues and is a further highly studied AGE (Sell and Monnier 1989). In 1991, the enzymatic metabolism of fructosamine adducts was also discovered by Horiuchi and Kurokawa—fructosyl-amino acid oxidase from bacteria catalysed the conversion of fructosyl-amino acids to the free amino acid, glucosone and hydrogen peroxide (Horiuchi and Kurokawa 1991).

In 1992, Schmidt and co-workers identified an AGE receptor protein from bovine lung endothelial cells—later shown to have a sequence mass of 42 kDa (Schmidt et al. 1992). This was the receptor for advanced glycosylation endproducts (RAGE) and is the best characterised of the AGE receptors.

Over the period 1994–1998 the inhibitor of AGE formation Pimagedine™ was evaluated in clinical trials for the prevention of overt nephropathy in clinical diabetes (ACTION I and ACTION II). The trials were eventually terminated due to safety concerns and apparent lack of efficacy (Thornalley 2003c).

In 1996, Cerami and co-workers introduced the concept of “AGE breakers”—compounds that may cleave glycation derived crosslinks and reverse one of the damaging effects of glycation associated with ageing and disease. The prototype compound was N-phenacylthiazolium bromide (PTB; Vasan et al. 1996). Unfortunately this and related analogues had stability problems (Price et al. 2001; Thornalley and Minhas 1999).

In 1997, Shipanova et al. discovered argpyrimidine—a major fluorescence AGE formed from MG (Shipanova et al. 1997). Vlassara and co-workers used the term “glycotoxins” to refer to highly reactive AGE intermediates and initiated a series of on-going studies assessing the physiological effects of AGEs in the diet on health (Koschinsky et al. 1997).

In 2000, Delpierre et al. discovered fructosamine 3-kinase which catalyses the phosphorylation of fructosamine and fructosamine residues in proteins leading to the de-glycation and repair of early glycated proteins (Delpierre et al. 2000). A time-line diagram of glycation research development is given in Fig. 3.
Fig. 3

Timeline showing key developments in glycation research from 1900 to 2000. GA3P glyceraldehyde-3-phosphate

In the last decade there has been a marked expansion of glycation-related research—particularly with application of proteomics to detection and quantitation of glycated proteins and glycation free adducts, cell signalling studies in response to RAGE and other response, functional genomics of components of enzymatic defence against glycation (fructosamine 3-kinase, glyoxalase 1 and aldoketo reductases), therapeutics development, food processing and other applications. The rate of scientific publication on glycation doubled in this time—Fig. 4.
Fig. 4

Publication frequency in glycation research over the period 1979–2009. The database used was ISI Web of knowledge and search terms were: glycation, glycated, non-enzymatic glycosylation, non-enzymic glycosylation and glucosylatyed. Total count: 18,928. Inclusion of the terms glycohaemoglobin and glycosylated haemoglobin increased the count to 30,100—most papers relating to monitoring of glycemic control in diabetes

Importance of protein glycation

In biology, protein glycation is implicated in the low level endogenous damage to the proteome with the ubiquitous presence of an enzymatic defence akin to that of antioxidants to counter it. The enzymatic defence against glycation consists of enzymes that repair early glycated proteins and prevent glycation by metabolising dicarbonyl glycating agents: fructosamine 3-kinase (Delpierre et al. 2000), fructosamine 3-kinase-related protein (Delplanque et al. 2004) and others; and glyoxalase 1 (Thornalley 2003b) and aldoketo reductases 1A4, 1B1 and 1B3 (aldose reductase; Baba et al. 2009). The imbalance of glycating agents and enzymatic defence against glycation in favour of glycating agents has been termed carbonyl stress and is thought to contribute to ageing and disease (Miyata et al. 1999; Morcos et al. 2008; Xue et al. 2008). Emerging evidence of a chaperone function of lens crystallins (Gangadhariah et al. 2010) and a regulatory decrease in the enzymatic defence against glycation in inflammatory signalling (Thornalley 2007) is suggesting a beneficial functional role of protein glycation in some instances.

In the clinical setting, increased formation and steady-state accumulation of glycated proteins have been linked to disease development and progression—particularly diabetes and its vascular complications (Ahmed et al. 2005a; McCance et al. 1993), renal failure (Agalou et al. 2005; Miyata et al. 2001), cardiovascular disease and Alzheimer’s disease (Ahmed et al. 2004a; Chen et al. 2004; Rabbani et al. 2010). Involvement in arthritis and cirrhosis (Ahmed et al. 2004b, 2006), mood affective disorders—anxiety and Schizophrenia (Arai et al. 2010; Hambsch et al. 2010), Parkinson’s disease (Kurz et al. 2010) and other disease is emerging.

In food and nutrition, glycation is increased in culinary processing—particularly during heating and alkaline-treated bakery products (Ahmed et al. 2005b; Henle 2001). Glycation may impair nutritional quality, influence intestinal microflora, post-prandial vascular dysfunction, glucose tolerance and obesity (Birlouez-Aragon et al. 2010; Tuohy et al. 2006). The contribution of glycation adducts in proteins in food to total physiological exposure to glycation adducts and pathological effect remains controversial (Henle 2007; Uribarri et al. 2010). Glycation adduct contents of food, pre-absorptive processing and metabolic transit of protein glycation adducts (bioavailability, clearance and residence time in the body) and functional effects remain critical issues for further investigation.

In pharmacology and toxicology, multidrug resistance associated with overexpression of glyoxalase 1 has suggested a role of dicarbonyl glycation in the mechanism of action of cytotoxic antitumour agents (Thornalley 2003a). Fortunately tumours with overexpression of glyoxalase—now known to be linked to Glo1 gene amplification (Santarius et al. 2010)—are sensitive to glyoxalase inhibitor therapy (Sakamoto et al. 2001; Thornalley et al. 1996). Drug development to increase dicarbonyl glycation by inhibition of glyoxalase 1 will likely find use in overcoming tumour multidrug resistance, and drug and dietary supplement development to decrease glycation will find use as disease therapeutics and prophylaxis for healthy ageing (Morcos et al. 2008).

Technological processing of medical products such as dialyse fluids for renal replacement therapy (Linden et al. 2002; Schalkwijk et al. 1999) and food and beverages such as sweetened cola drinks involve formation and exposure to dicarbonyl glycating agents (Lo et al. 2008). Formation of crosslinking in proteins for tanning and desired browning of skin in lotions also involves glycation (Avery and Bailey 2008; Petersen et al. 2004). Further development will optimise the levels of glycating agents and types and levels of glycation adducts for technological application.

A forum to focus on glycation research

Glycation research poses great challenges to scientists. The extent of glycation of proteins in physiological samples is typically low and the range of adducts diverse in physiological systems. In culinary-processed proteins the content of glycation adducts is high but they are often difficult to analyse intact and resistant to release without decomposition for analysis. Risk of formation of glycation adducts and some of their precursors during pre-analytic processing is nearly always significant and overestimation of analytes is often possible. The physiological effects of protein glycation are diverse, intricate and complex. Some long-held views on glycation hold good and some have been revised in recent years. To address these issues we seek to publish the best practise in experimental techniques, present experimental results from rigorous and imaginative testing of hypotheses, re-appraisal of old concepts and introduction of new ones, and discuss conflicting and confounding outcomes from all who involved in glycation research and beyond. This will be done in an environment of constructive expert peer review and supportive editorial management. The following articles are mainly collaborative efforts of expert and authoritative views on different areas of glycation research. They provide an excellent start.

We welcome the chance to publish your experimental reports, reviews and opinion on glycation research in future issues.


We thank Professor Gert Lubec for embracing this initiative on glycation research and our colleagues who have given their time and efforts in support of it.

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Clinical Sciences Research InstituteWarwick Medical School, University of Warwick, University HospitalCoventryUK

Personalised recommendations